High-dose intravenous immunoglobulin treatment of multiple sclerosis
High-dose intravenous immunoglobulin treatment of multiple sclerosis
复制标题
大剂量静脉注射免疫球蛋白治疗多发性硬化症
作者：
L. Durelli;G. Isoardo
抽象。多发性硬化症的病理基础的审查，看看是否有许多免疫效果，如果静脉注射免疫球蛋白可能会产生一些好处，在什么水平。这可能是由于广泛的IVIg和免疫系统之间的相互作用，这是在这次审查中分析。巨噬细胞Fc受体的饱和和阻断、抗独特型效应、内皮细胞活化的减少和超抗原中和抗体可能参与IVIg在免疫异常性脱髓鞘疾病中的作用。此外，IVIg促进病毒诱导的实验性脑脊髓炎的髓鞘再生。在MS中进行的IVIg试验表明复发率（RR）和磁共振成像上钆增强病变的出现减少。此外，静脉注射免疫球蛋白被认为是一种有前途的治疗，以减少在产后期间的RR。然而，关于继发性进展性MS的研究未能证明IVIg对残疾的影响，并且在两项大型试验中IVIg未能改善稳定的视觉和运动缺陷。
Abstract. A review of the pathological basis of multiple sclerosis is presented to see whether the many immunological effects if IVIg may exert some benefit and at what level. This is probably due to the wide spectrum of interactions between IVIg and the immune system, which are analyzed in this review. Macrophage Fc receptor saturation and block, anti-idiotypic effect, reduction of endothelial cell activation and superantigen-neutralizing antibodies are probably involved in the action of IVIg in dysimmune demyelinating diseases. Furthermore, IVIg promote remyelination in virus-induced experimental encephalomyelitis. Trials on IVIg in MS demonstrated a reduction of relapse rate (RR) and appearance of gadolinium-enhancing lesions on magnetic resonance imaging. Furthermore IvIg are regarded as a promising treatment to reduce RR in post-partum period. However, studies on secondary-progressive MS failed to demonstrate an IVIg effect on disability and IVIg failed to improve stabilized visual and motor deficits in two large trials.
对不同革兰氏阴性菌脂多糖的不同免疫显性糖具有特异性的单克隆抗体之间共有的独特型。
DOI：
10.1073/pnas.79.5.1616
发表时间：
1982
影响因子：
11.1
作者：
Hiernaux,J;Bona,CA
通讯作者：
Bona,CA
在多发性硬化症模型中促进中枢神经系统髓鞘再生的单克隆自身抗体是由种系免疫球蛋白基因编码的天然自身抗体。
DOI：
--
发表时间：
1995
期刊：
Journal of immunology (Baltimore, Md. : 1950)
影响因子：
--
作者：
Miller,DJ;Rodriguez,M
通讯作者：
Rodriguez,M